NCI-H889細(xì)胞
生長狀態(tài)： 懸浮生長，簇狀懸浮
器官來源： 肺
是否是腫瘤細(xì)胞： 1
物種來源： 人
ATCC Number： CRL-5817?
相關(guān)**： 小細(xì)胞肺癌
年限： stage E
運(yùn)輸方式： 凍存運(yùn)輸
數(shù)量： 大量
細(xì)胞形態(tài)： 上皮樣
Designations: NCI-H889 [H889]
Depositors: AF Gazdar, JD Minna
NCI-H889細(xì)胞Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: clusters in suspension
Organism: Homo sapiens
Morphology: epithelial
Source: Organ: lung
Tumor Stage: stage E
Disease: carcinoma; classic small cell lung cancer
Derived from metastatic site: lymph node
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions: NCI-H889細(xì)胞The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.
DNA Profile (STR): Amelogenin: X
CSF1PO: 10
D13S317: 11
D16S539: 8
D5S818: 12
D7S820: 8,9
THO1: 8,9.3
TPOX: 8,9
vWA: 17
Age: 69 years
Gender: female
Ethnicity: Caucasian
Comments: NCI-H889細(xì)胞This line was derived by A.F. Gazdar, H.K. Oie, J.D. Minna and associates from a lymph node metastasis taken from a patient prior to therapy.
The cells express reduced levels of p53 mRNA compared to levels found in normal lung.
There is a point mutation, a G to C transition (TGC to TCC), which results in a substitution of a serine for cysteine at codon 242.
The cells carry the K-ras 12 mutation.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation of the suspension with subsequent resuspension in fresh medium. Add medium as the cell density increases.
Preservation: Culture medium, 95%; DMSO, 5%
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 1806: NCI-H889細(xì)胞Takahashi T, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494
23570: . NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996.
